Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients
YANTAI, China, Nov. 15, 2023. RemeGen Co., Ltd. ( " RemeGen " or " the Company " ), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Arthritis | Biotechnology | China Health | Clinical Trials | Pharmaceuticals | Rheumatoid Arthritis | Rheumatology